KYNB

#4538
Kyntra Bio, Inc. Common Stock
7.37 USD
+4.10%
Settore:
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
7.37
7.37
Intervallo Annuale
6.32
9.70
Variazione giornaliera
+4.10%
Variazione Mensile
+3.08%
Variazione di 6 mesi
-22.50%
Variazione Annuale
-22.50%
Chiusura Precedente
7.08
Apertura
7.37
Bid
Ask
Minimo
7.37
High
7.37
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 202020212022202320242025 TTM

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.